• Home
  • About
  • Clinical
  • Authors
  • GP Opinion
  • Videos & Podcasts
  • Professional
  • Most read this year
  • Comments policy
  • RACGP
Menu

Filter
Mixed response to latest Solidarity trial COVID findings

Mixed response to latest Solidarity trial COVID findings

No therapeutics in the trial – including remdesivir – were found to affect on mortality or illness duration, but some say there is hope.


Gold standard trial finds remdesivir shortens duration of COVID-19

Gold standard trial finds remdesivir shortens duration of COVID-19

The results have confirmed doctors’ experiences of treating COVID patients in Australia.


US purchasing global supply of COVID-19 drug raises ethical questions

US purchasing global supply of COVID-19 drug raises ethical questions

Gilead Sciences has donated a supply of remdesivir to Australia’s national medical stockpile. But what if cases continue to rise?


Antiviral becomes first recommended treatment for COVID-19

Antiviral becomes first recommended treatment for COVID-19

newsGP speaks with the Chair of Australia’s National Covid-19 Clinical Evidence Taskforce about the recommended use of remdesivir.


Remdesivir under review by national COVID-19 taskforce

Remdesivir under review by national COVID-19 taskforce

newsGP speaks to taskforce Chair Associate Professor Julian Elliott about the latest guidance for the care of coronavirus patients.


Remdesivir and COVID-19: What GPs need to know

Remdesivir and COVID-19: What GPs need to know

It has become the first therapy for COVID-19 to receive FDA approval for emergency use – but evidence of its effectiveness remains mixed.


RACGP newsGP ArticlesnewsGP

Terms and conditions | Privacy statement | RACGP | recruitGP | AJGP

© 2018 The Royal Australian College of General Practitioners (RACGP) ABN 34 000 223 807